Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Quetiapine Monotherapy Has Benefits for Treatment of Generalized Anxiety: Presented at APA By Danny Kucharsky TORONTO, CANADA -- May 29, 2006 -- Quetiapine may be a useful option for the treatment of generalized anxiety disorder (GAD), concludes a pilot study presented here at the American Psychiatric Association Annual Meeting (APA). The double-blind, placebo-controlled trial was presented on May 24th by investigator Olga Brawman-Mintzer, MD, associate professor, public psychiatry division, Medical University of South Carolina, and core investigator, Ralph Johnson VA Medical Center, Charleston, South Carolina. Following a 1-week placebo run-in, 38 patients with a primary diagnosis of GAD were randomized to 6 weeks of treatment with quetiapine 25 to 300 mg/day or placebo. Twelve of 19 patients in the quetiapine group and 16 of 19 patients in the placebo group completed the trial. Seven patients (5 in the quetiapine group) withdrew due to adverse events. These were mostly mild to moderate and the most common were fatigue and somnolence. At endpoint, decreases in Hamilton Anxiety Rating Scale total scores in the quetiapine and placebo groups but not statistically different. However, observed case analysis at weeks 2 and 4 showed significant improvement in the quetiapine group compared with the placebo group at week 2 (-11.1 vs -5.9, P <.05) and at week 4 (-13.7 vs -8.6, P <.05). Quetiapine patients also had numerically different reductions in all other outcome measures, but the differences compared with placebo were not statistically significant. Both the response rate and remission rate at endpoint were greater in the quetiapine group (57.9 vs 36.8% and 42.1 vs 21.1% of patients, respectively), but again, differences were not statistically significant. Despite the small sample size, the preliminary results suggest evidence of improvement in the treatment of GAD or treatment-resistant GAD, Dr. Brawman-Mintzer said. Further studies are warranted, she added. "I think it is going to be an interesting area to pursue," Dr. Brawman-Mintzer said. "The data are encouraging enough that there will be large-scale information available soon enough." The study was sponsored by AstraZeneca. [Presentation title: Quetiapine Monotherapy in Patients With GAD. Abstract NR634.] E-mail this page to a friend or colleague! To print, use this version